Company: DAWN
Filing Date: 2025-03-06
Form Type: 10-K/A
Source: 0000950170-25-034878
Chunk: 43

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-03-06
Form: 10-K/A
Chunk 43
---
 subject to any material legal proceedings, and to the best of its knowledge, no material legal proceedings are currently pending or threatened. Indemnification Agreements In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for indemnification for certain liabilities. The exposure under these agreements is unknown because it involves claims that may be made against it in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations. The Company also has indemnification obligations to its directors and executive officers for specified events or occurrences, subject to some limits, while they are serving at its request in such capacities. There have been no claims to date, and the Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company had no t recorded any liabilities for these agreements as of December 31, 2024 and 2023 .

8. Common Stock

Pursuant to its certificate of incorporation, the Company is authorized to issue500.0million shares of common stock at a par value of $0.0001per share. As ofDecember 31, 2024,101,116,162shares of common stock were issued and outstanding.

The Company has reserved shares of common stock for future issuances as follows:

|                                               |     | December 31, 
 2024         |            |
|:----------------------------------------------|:----|:-------------|-----------:|
| Common stock options issued and outstanding   |     |              | 12,127,435 |
| Common stock available for future grants      |     |              |  3,482,006 |
| Common stock available for ESPP               |     |              |  2,421,745 |
| Restricted stock units issued and outstanding |     |              |  1,774,287 |
| Pre-funded warrants                           |     |              |  1,517,241 |
| Total                                         |     |              | 21,322,714 |

<div align='center'>F-28</div>

2024 Private Placement In July 2024, the Company entered into a securities purchase agreement with certain institutional and accredited investors, or the PIPE Investors, pursuant to which the Company agreed to sell and issue to the PIPE Investors in a private placement, or the Private Placement, an aggregate of (